The cost-effectiveness of screening for chronic hepatitis B infection in the United States

Clinical Infectious Diseases

Volumn 52, Issue 11, 2011, Pages 1294-1306

  Eckman, Mark H ^a,c   Kaiser, Tiffany E ^b   Sherman, Kenneth E ^b  

^a Center for Clinical Effectiveness   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; TENOFOVIR;

ARTICLE; CHRONIC HEPATITIS; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; HEPATITIS B; MASS SCREENING; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNITED STATES; VIRUS RESISTANCE;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; MALE; MASS SCREENING; MODELS, STATISTICAL; PREVALENCE; UNITED STATES;

EID: 79957441465     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir199     Document Type: Article

References (60)

1. Disease burden from hepatitis A, B, and C in the United States. 2007. http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/disease-burden.pdf. Accessed 22 January 2008.
2. Committee on the Prevention and Control of Viral Hepatitis Infections. Hepatitis and liver cancer. Washington, DC: Institute of Medicine-National Academy of Sciences, 2010.
3. US Preventive Services Task Force. Screening for hepatitis B virus infection recommendation statement. 2004. Rockville, MD. http://www.ahrq.gov/ clinic/3rduspstf/hepbscr/hepbrs.htm. Accessed 16 March 2009.
4. Centers for Disease Control and Prevention. Testing and public health management of persons with chronic hepatitis B virus infection. 2008. Atlanta, GA. http://www.cdc.gov/hepatitis/HBV/TestingChronic. htm#section1. Accessed 22 May 2009.
5. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: A costeffectiveness analysis. Ann Intern Med 2005; 142:821-31. (Pubitemid 40664041)
6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-39. (Pubitemid 46374607)
7. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference statement: Management of hepatitis B. Ann Intern Med 2009; 150:104-10.
8. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-41.
9. Kim SY, Billah K, Lieu TA, Weinstein MC. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med 2006; 30:498-506.
10. Weitzman G, Jacobson I. Cost-effectiveness in hepatitis B. Ann Intern Med 2005; 143:757-8.
11. Brennan MR, Spiegel BM, Martin P, Kanwal F. Cost-Effectiveness in Hepatitis B. Ann Intern Med 2005; 143:758-9.
12. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127:855-65.
13. Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat 2007; 14:751-66. (Pubitemid 47561579)
14. Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAgnegative chronic hepatitis B: A cost-effectiveness analysis. Aliment Pharmacol Ther 2008; 27:1240-52. (Pubitemid 351697278)
15. Yuan Y, Iloeje UH, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm 2008; 14:21-33. (Pubitemid 351325191)
16. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147:460-9. (Pubitemid 351664518)
17. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999; 89:14-8. (Pubitemid 29281961)
18. Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008: 1-20. Atlanta, GA. http://www.cdc.gov/ mmwr/preview/mmwrhtml/rr5708a1.htm. Accessed 22 May 2009.
19. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2:87-106. (Pubitemid 38180462)
20. Lau J, Kassirer JP, Pauker SG. Decision Maker 3.0. Improved decision analysis by personal computer. Med Decis Making 1983; 3:39-43. (Pubitemid 13020642)
21. Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis-United States, 2005. MMWR Surveill Summ 2007; 56:1-24.
22. Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: A clinical and histologic evaluation of 242 cases.Hepatology 1987; 7:302-6. (Pubitemid 17062720)
23. Sakugawa H, Nakasone H, Nakayoshi T, et al. Correlation between serum transaminase activity and virus load among patients with chronic liver disease type B. Hepatol Res 2001; 21:159-68. (Pubitemid 32899086)
24. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
25. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522-7.
26. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-86. (Pubitemid 43374518)
27. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-52.
28. Choi SH, Lee HH, Lee DS, et al. Clinicopathological features of incidental hepatocellular carcinoma in liver transplantation. Transplant Proc 2004; 36:2293-4. (Pubitemid 39550819)
29. Xu B, Hu DC, Rosenberg DM, et al. Chronic hepatitis B: A long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol 2003; 18:1345-52. (Pubitemid 38045846)
30. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: Mortality after 25 years. Gut 2008; 57:84-90.
31. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135:759-68. (Pubitemid 33051260)
32. Villeneuve JP. The natural history of chronic hepatitis B virus infection. J Clin Virol 2005; 34(Suppl 1):S139-42.
33. Time to transplant, 1997 to 2006 new liver waiting list registrations, table 15.2 2007. http://www.optn.org/AR2007/waitlist-outcomes.htm. Accessed 2 October 2009.
34. Unadjusted patient survival, deceased donor liver transplants survival at 3 months, 1 year, 3 years, and 5 years, table 9.14a 2007. http://www.optn.org/ AR2007/survival-rates.htm. Accessed 2 October 2009.
35. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: A cohort study of 297 patients. Am J Gastroenterol 2002; 97:2886-95. (Pubitemid 35265444)
36. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290:228-37. (Pubitemid 37430062)
37. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-95. (Pubitemid 41007823)
38. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAgnegative chronic hepatitis B. N Engl J Med 2004; 351:1206-17. (Pubitemid 39296307)
39. Lai CL, Yuen MF. Chronic hepatitis B-new goals, new treatment. N Engl J Med 2008; 359:2488-91.
40. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19:1276-82.
41. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007; 12:1295-303.
42. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001; 33:1527-32. (Pubitemid 32496991)
43. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-31.
44. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-22. (Pubitemid 37500436)
45. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-55.
46. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: A multinational study of utilities from infected and uninfected persons. Value Health 2008; 11:527-38. (Pubitemid 351712982)
47. Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004; 38(Suppl 3):S144-7.
48. 2008 red book. editor: Nermin Shenouda. Montvale, NJ: Thomson Medical Economics, 2008.
49. Centers for Medicare and Medicaid Services. Clinical laboratory fee schedule. 2008 clinical laboratory fee schedule file. Hyattsville, MD: US Department of Health and Human Services, 2008.
50. Centers for Medicare and Medicaid Services. Physician fee schedule. 2008 national physician fee schedule relative value file. Hyattsville, MD: US Department of Health and Human Services, 2008.
51. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine, 1st ed. New York: Oxford University Press, 1996.
52. McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: A systematic review. Med Decis Making 2008; 28:582-92. (Pubitemid 351989999)
53. Ong SC, Mak B, Aung MO, Li SC, Lim SG. Health-related quality of life in chronic hepatitis B patients. Hepatology 2008; 47:1108-17. (Pubitemid 351547897)
54. Owens DK, Cardinalli AB, Nease RF Jr. Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Qual Life Res 1997; 6:77-86. (Pubitemid 27110098)
55. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001; 96:579-83.
56. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 5:157-77. (Pubitemid 16130640)
57. Ribes J, Cleries R, Rubio A, et al. Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. Int J Cancer 2006; 119:687-94. (Pubitemid 43955725)
58. Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: A cross-sectional study of Asians in California. Hepatology 2007; 46:1034-40. (Pubitemid 350144768)
59. Welch S, Chiang B, Shadday P, Brosgart CL. Estimated prevalence of chronic hepatitis B in foreign-born persons living in the United States by country/region of origin. Hepatology 2008; 48:687A-8A.
60. Han SH. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B. Drugs 2006; 66:1831-51.